Clinical Trials in Italy / NCT07476495
Recruiting
Observational
Insights on Dissemination of Lung Cancer
NCT07476495 · tracked via the Priya Life Science Italy tracker
Condition(s) studied
Oncology & Epidemiology & Lung Cancer
Study summary
In patients with resectable NSCLC treated with surgery alone or with surgery as part of a multimodal treatment; CTC, ctDNA, STAS, and lymph node micrometastasis levels will be evaluated to see if they are associated with recurrence patterns and long-term outcomes.
Eligibility
Inclusion Criteria:
* Age ≥ 18 years;
* Preoperative diagnosis of resectable stage cIA-cIIIA NSCLC (adenocarcinoma or squamous cell carcinoma);
* Patients deemed fit for surgical or multimodal treatment;
* Informed consent obtained;
* Treatment, including multimodal treatment, involving surgery.
Exclusion Criteria:
* Histology other than adenocarcinoma or squamous cell carcinoma;
* Other neoplastic diseases concurrent with or undergoing treatment or treated with systemic therapies in the previous three years;
* Age \<18 years;
* No need for surgery.
Primary outcome measure(s)
- Measurement and quantification of CTC and ctDNA — From enrollment to the end of study at 36 months
* CTC (Circulating Tumor Cells) using CellSearch® (FDA-cleared) number cells per 7.5 mL of whole blood * ctDNA (Circulating Tumor DNA) using NGS (Illumina platform) - Variant Allele Frequency VAF (%)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| IRCCS Azienda Ospedaliero-Università di Bologna | Bologna | Bologna | Recruiting |
More IRCCS Azienda Ospedaliero-Universitaria di Bologna trials in Italy
Multi-Dimensional Genomic Dissection of Ring Chromosome 14 Syndrome
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07476495 on ClinicalTrials.gov ↗ ← All trials in Italy